Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

369 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Tzogani K, Florez B, Markey G, Caleno M, Olimpieri OM, Melchiorri D, Hovgaard DJ, Sarac SB, Penttilä K, Lapveteläinen T, Salmonson T, Bergh J, Gisselbrecht C, Pignatti F. Tzogani K, et al. Among authors: gisselbrecht c. ESMO Open. 2019 Sep 8;4(5):e000570. doi: 10.1136/esmoopen-2019-000570. eCollection 2019. ESMO Open. 2019. PMID: 31555488 Free PMC article. Review.
European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
Tzogani K, Yu Y, Meulendijks D, Herberts C, Hennik P, Verheijen R, Wangen T, Dahlseng Håkonsen G, Kaasboll T, Dalhus M, Bolstad B, Salmonson T, Gisselbrecht C, Pignatti F. Tzogani K, et al. Among authors: gisselbrecht c. ESMO Open. 2019 Nov;4(6):e000606. doi: 10.1136/esmoopen-2019-000606. ESMO Open. 2019. PMID: 32392175 Free PMC article. Review.
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I, Tzogani K, van Hennik P, de Graeff P, Schmitt P, Mueller-Berghaus J, Salmonson T, Gisselbrecht C, Laane E, Bergmann L, Pignatti F. Gravanis I, et al. Among authors: gisselbrecht c. Oncologist. 2016 Jan;21(1):102-9. doi: 10.1634/theoncologist.2015-0276. Epub 2015 Nov 30. Oncologist. 2016. PMID: 26621039 Free PMC article.
The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy.
Tzogani K, Camarero Jiménez J, Garcia I, Sancho-López A, Martin M, Moreau A, Demolis P, Salmonson T, Bergh J, Laane E, Ludwig H, Gisselbrecht C, Pignatti F. Tzogani K, et al. Among authors: gisselbrecht c. Oncologist. 2017 Nov;22(11):1339-1346. doi: 10.1634/theoncologist.2017-0184. Epub 2017 Sep 21. Oncologist. 2017. PMID: 28935772 Free PMC article. Clinical Trial.
EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.
Tzogani K, van Hennik P, Walsh I, De Graeff P, Folin A, Sjöberg J, Salmonson T, Bergh J, Laane E, Ludwig H, Gisselbrecht C, Pignatti F. Tzogani K, et al. Among authors: gisselbrecht c. Oncologist. 2018 May;23(5):631-636. doi: 10.1634/theoncologist.2017-0301. Epub 2017 Nov 30. Oncologist. 2018. PMID: 29192015 Free PMC article. Review.
EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
Tzogani K, Penninga E, Schougaard Christiansen ML, Hovgaard D, Sarac SB, Camarero Jimenez J, Garcia I, Lafuente M, Sancho-López A, Salmonson T, Gisselbrecht C, Pignatti F. Tzogani K, et al. Among authors: gisselbrecht c. Oncologist. 2018 May;23(5):594-602. doi: 10.1634/theoncologist.2017-0328. Epub 2018 Jan 25. Oncologist. 2018. PMID: 29371479 Free PMC article. Clinical Trial.
The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S, Kjeken R, Niederlaender C, Markey G, Saunders TS, Opsata M, Moltu K, Bremnes B, Grønevik E, Muusse M, Håkonsen GD, Skibeli V, Kalland ME, Wang I, Buajordet I, Urbaniak A, Johnston J, Rantell K, Kerwash E, Schuessler-Lenz M, Salmonson T, Bergh J, Gisselbrecht C, Tzogani K, Papadouli I, Pignatti F. Ali S, et al. Among authors: gisselbrecht c. Oncologist. 2020 Feb;25(2):e321-e327. doi: 10.1634/theoncologist.2019-0233. Epub 2019 Oct 16. Oncologist. 2020. PMID: 32043764 Free PMC article. Review.
EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
Tzogani K, Penttilä K, Lähteenvuo J, Lapveteläinen T, Lopez Anglada L, Prieto C, Garcia-Ochoa B, Enzmann H, Gisselbrecht C, Delgado J, Pignatti F. Tzogani K, et al. Among authors: gisselbrecht c. Oncologist. 2021 Jan;26(1):70-76. doi: 10.1002/onco.13592. Epub 2020 Nov 23. Oncologist. 2021. PMID: 33179377 Free PMC article. Clinical Trial.
The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease.
Delgado J, Voltz C, Stain M, Lapveteläinen T, Urach S, Lähteenvuo J, Penttilä K, Gisselbrecht C, Enzmann H, Pignatti F. Delgado J, et al. Among authors: gisselbrecht c. Hemasphere. 2021 Jun 28;5(7):e604. doi: 10.1097/HS9.0000000000000604. eCollection 2021 Jul. Hemasphere. 2021. PMID: 34235401 Free PMC article. Review.
The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma.
Delgado J, Papadouli I, Sarac SB, Moreau A, Hovgaard D, Gisselbrecht C, Enzmann H, Pignatti F. Delgado J, et al. Among authors: gisselbrecht c. Hemasphere. 2021 Nov 18;5(12):e666. doi: 10.1097/HS9.0000000000000666. eCollection 2021 Dec. Hemasphere. 2021. PMID: 34805769 Free PMC article. Review.
369 results